Ertas, I E Izmir Tepecik Training and Research Hospital - Clinic of Ggynaecologic Oncology, Turkey , Doğan, A Izmir Tepecik Training and Research Hospital - Clinic of Ggynaecologic Oncology, Turkey , Özdemir, A Izmir Tepecik Training and Research Hospital - Clinic of Ggynaecologic Oncology, Turkey , Solmaz, U Izmir Tepecik Training and Research Hospital - Clinic of Ggynaecologic Oncology, Turkey , Göklü, R Izmir Tepecik Training and Research Hospital - Clinic of Ggynaecologic Oncology, Turkey , Yıldırım, Y Izmir Tepecik Training and Research Hospital - Clinic of Ggynaecologic Oncology, Turkey

The effect of adjuvant treatment modalities on survival outcomes in cytoreductive surgery performed patients with advanced stage uterine sarcomas

14820

Aim: To analyse the effect of adjuvant treatment modalities on survival outcomes in cytoreductive surgery (CRS) performed on patients diagnosed with advanced stage uterine sarcomas. Materials and Methods: Between the years of 1/1994–1/2009; among (n=122) patients with uterine sarcoma that were diagnosed and treated at our center, n=26 (21%) who had advanced (FIGO stage III and IV) disease were the subject of this retrospective study. The stage of the disease, tumor histology, presence of lymphadenectomy, optimality of cytoreductive surgery, adjuvant radiotherapy (RT) and chemotherapy (CT) applications, disease-free survival (DFS) and overall survival (OVS) rates were the main outcome measures. Data were presented by performing descriptive analyses, Kaplan-Meier and the log-rank test. Results: Histologically, cases consist of 9 (34.6%) leiomyosarcoma;3 (11.4%) endometrial stromal sarcoma and 14 (54%) carsinosarcoma. Systematic lymphadenectomy was performed in the forms only bilateral pelvic (n = 9); bilateral pelvic + para-aortic (n=17). Optimal cytoreduction was achieved in 23 (88%) of 26 patients. Only CT (n = 10) and CT + RT (n=16) were applied as adjuvant treatments. The mean survival of patient groups on which (CRS+ adjuvant CT)–(CRS+adjuvant CT+RT) were performed was determined as [12.6–42.3] months (p 0.05) in terms of DFS and, [21.8–52.8] months (p 0.01) in terms of OVS, respectively. Conclusion: Due to the low quantity of patients, different tumor types and different CT regimens, data of the treatment modalities from this particular patient setting are inconclusive, especially in terms of effectiveness of adjuvant CT alone following CRS. But there is evidence for the combination of adjuvant CT and RT following CRS provides significantly higher DFS and OVS rates.

179

Uterine sarcomas , advanced stage , cytoreductive surgery , adjuvant chemotherapy , adjuvant radiotherapy

Ege Journal Of Medicine

184